U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H21N3O.C6H8O7
Molecular Weight 391.4174
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIETHYLCARBAMAZINE CITRATE

SMILES

CCN(CC)C(=O)N1CCN(C)CC1.C(C(=O)O)C(CC(=O)O)(C(=O)O)O

InChI

InChIKey=PGNKBEARDDELNB-UHFFFAOYSA-N
InChI=1S/C10H21N3O.C6H8O7/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-9H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

HIDE SMILES / InChI

Molecular Formula C10H21N3O
Molecular Weight 199.2936
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C6H8O7
Molecular Weight 192.1238
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including http://filobase.bicpu.edu.in/banocide.pdf

Diethylcarbamazine is used in humans, dogs and cats for the treatment of parasitic infections, including pulmonary eosinophilia, loiasis, and lymphatic filariasis. The exact mechanism of its action is unknown, however some studies showed the involvment of inducible nitric-oxide synthase and the cyclooxygenase pathway. Although there is no information on whether the drug is marketed in the USA and Europe, it is currently used in India.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
BANOCIDE

Approved Use

Used for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori.
Curative
BANOCIDE

Approved Use

Used for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori.
Curative
BANOCIDE

Approved Use

Used for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
500 ng/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIETHYLCARBAMAZINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
637 ng/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIETHYLCARBAMAZINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5840 ng × h/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIETHYLCARBAMAZINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
7220 ng × h/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIETHYLCARBAMAZINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
14.6 h
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIETHYLCARBAMAZINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
11.4 h
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIETHYLCARBAMAZINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
6 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg/kg, 1 times / day
Sources:
unhealthy, 12 to 69 years
n = 11
Health Status: unhealthy
Condition: filariasis
Age Group: 12 to 69 years
Sex: M+F
Population Size: 11
Sources:
Other AEs: Fever, Pruritus...
Other AEs:
Fever (63.6%)
Pruritus (9.1%)
Giddiness (9.1%)
Joint ache (9.1%)
Sources:
2 mg/kg 3 times / day multiple, oral
Studied dose
Dose: 2 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg/kg, 3 times / day
Sources:
unhealthy, 13 to 46 years
n = 11
Health Status: unhealthy
Condition: filariasis
Age Group: 13 to 46 years
Sex: M+F
Population Size: 11
Sources:
Other AEs: Fever, Nausea...
Other AEs:
Fever
Nausea (27.3%)
Vomiting (18.2%)
Abdominal discomfort (9.1%)
Sources:
50 mg multiple, oral
Studied dose
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 37 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 37 years
Sex: M
Population Size: 10
Sources:
Other AEs: Lymphadenopathy, Papular urticarial eruption...
Other AEs:
Lymphadenopathy (100%)
Papular urticarial eruption (30%)
Proteinuria (10%)
Visual field constriction (20%)
Optic nerve pallor (10%)
Corneal opacity (90%)
Anterior uveitis (10%)
Chorioretinitis (10%)
Sources:
300 mg multiple, topical
Studied dose
Dose: 300 mg
Route: topical
Route: multiple
Dose: 300 mg
Sources:
unhealthy, 40 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 40 years
Sex: M
Population Size: 10
Sources:
Other AEs: Lymphadenopathy, Papular urticarial eruption...
Other AEs:
Lymphadenopathy (100%)
Papular urticarial eruption (70%)
Proteinuria (30%)
Visual field constriction (10%)
Optic nerve pallor (20%)
Corneal opacity (80%)
Anterior uveitis (30%)
Chorioretinitis (30%)
Sources:
6 mg/kg 1 times / day single, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 6 mg/kg, 1 times / day
Co-administed with::
ivermectin(200 ug/kg; single)
albendazole(400 mg; single)
Sources:
unhealthy, median age 35 years
n = 43
Health Status: unhealthy
Condition: Filariasis
Age Group: median age 35 years
Sex: M+F
Population Size: 43
Sources:
Other AEs: Fatigue, Nausea...
Other AEs:
Fatigue (grade 2, 5%)
Nausea (grade 2, 2%)
Vomiting (grade 2, 2%)
Joint pain (grade 2, 2%)
Eye swelling (grade 2, 2%)
Rash (grade 2, 2%)
Dyspnea (grade 2, 2%)
Sources:
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Other AEs: Fever, Headache...
Other AEs:
Fever (69%)
Headache (65%)
Vertigo (57%)
Malaise (49%)
Chills (45%)
Joint pain (40%)
Abdominal pain (37%)
Chest pain (33%)
Nausea (28%)
Neck pain (24%)
Vomiting (16%)
Muscular pain (14%)
Lymph node tenderness (38%)
Epididymal tenderness (34%)
Nodule (15%)
Tinnitus (8%)
Convulsion (2%)
Eruption (<1%)
Shock (<1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Fever 63.6%
6 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg/kg, 1 times / day
Sources:
unhealthy, 12 to 69 years
n = 11
Health Status: unhealthy
Condition: filariasis
Age Group: 12 to 69 years
Sex: M+F
Population Size: 11
Sources:
Giddiness 9.1%
6 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg/kg, 1 times / day
Sources:
unhealthy, 12 to 69 years
n = 11
Health Status: unhealthy
Condition: filariasis
Age Group: 12 to 69 years
Sex: M+F
Population Size: 11
Sources:
Joint ache 9.1%
6 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg/kg, 1 times / day
Sources:
unhealthy, 12 to 69 years
n = 11
Health Status: unhealthy
Condition: filariasis
Age Group: 12 to 69 years
Sex: M+F
Population Size: 11
Sources:
Pruritus 9.1%
6 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg/kg, 1 times / day
Sources:
unhealthy, 12 to 69 years
n = 11
Health Status: unhealthy
Condition: filariasis
Age Group: 12 to 69 years
Sex: M+F
Population Size: 11
Sources:
Fever
2 mg/kg 3 times / day multiple, oral
Studied dose
Dose: 2 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg/kg, 3 times / day
Sources:
unhealthy, 13 to 46 years
n = 11
Health Status: unhealthy
Condition: filariasis
Age Group: 13 to 46 years
Sex: M+F
Population Size: 11
Sources:
Vomiting 18.2%
2 mg/kg 3 times / day multiple, oral
Studied dose
Dose: 2 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg/kg, 3 times / day
Sources:
unhealthy, 13 to 46 years
n = 11
Health Status: unhealthy
Condition: filariasis
Age Group: 13 to 46 years
Sex: M+F
Population Size: 11
Sources:
Nausea 27.3%
2 mg/kg 3 times / day multiple, oral
Studied dose
Dose: 2 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg/kg, 3 times / day
Sources:
unhealthy, 13 to 46 years
n = 11
Health Status: unhealthy
Condition: filariasis
Age Group: 13 to 46 years
Sex: M+F
Population Size: 11
Sources:
Abdominal discomfort 9.1%
2 mg/kg 3 times / day multiple, oral
Studied dose
Dose: 2 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg/kg, 3 times / day
Sources:
unhealthy, 13 to 46 years
n = 11
Health Status: unhealthy
Condition: filariasis
Age Group: 13 to 46 years
Sex: M+F
Population Size: 11
Sources:
Anterior uveitis 10%
50 mg multiple, oral
Studied dose
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 37 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 37 years
Sex: M
Population Size: 10
Sources:
Chorioretinitis 10%
50 mg multiple, oral
Studied dose
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 37 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 37 years
Sex: M
Population Size: 10
Sources:
Optic nerve pallor 10%
50 mg multiple, oral
Studied dose
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 37 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 37 years
Sex: M
Population Size: 10
Sources:
Proteinuria 10%
50 mg multiple, oral
Studied dose
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 37 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 37 years
Sex: M
Population Size: 10
Sources:
Lymphadenopathy 100%
50 mg multiple, oral
Studied dose
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 37 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 37 years
Sex: M
Population Size: 10
Sources:
Visual field constriction 20%
50 mg multiple, oral
Studied dose
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 37 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 37 years
Sex: M
Population Size: 10
Sources:
Papular urticarial eruption 30%
50 mg multiple, oral
Studied dose
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 37 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 37 years
Sex: M
Population Size: 10
Sources:
Corneal opacity 90%
50 mg multiple, oral
Studied dose
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 37 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 37 years
Sex: M
Population Size: 10
Sources:
Visual field constriction 10%
300 mg multiple, topical
Studied dose
Dose: 300 mg
Route: topical
Route: multiple
Dose: 300 mg
Sources:
unhealthy, 40 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 40 years
Sex: M
Population Size: 10
Sources:
Lymphadenopathy 100%
300 mg multiple, topical
Studied dose
Dose: 300 mg
Route: topical
Route: multiple
Dose: 300 mg
Sources:
unhealthy, 40 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 40 years
Sex: M
Population Size: 10
Sources:
Optic nerve pallor 20%
300 mg multiple, topical
Studied dose
Dose: 300 mg
Route: topical
Route: multiple
Dose: 300 mg
Sources:
unhealthy, 40 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 40 years
Sex: M
Population Size: 10
Sources:
Anterior uveitis 30%
300 mg multiple, topical
Studied dose
Dose: 300 mg
Route: topical
Route: multiple
Dose: 300 mg
Sources:
unhealthy, 40 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 40 years
Sex: M
Population Size: 10
Sources:
Chorioretinitis 30%
300 mg multiple, topical
Studied dose
Dose: 300 mg
Route: topical
Route: multiple
Dose: 300 mg
Sources:
unhealthy, 40 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 40 years
Sex: M
Population Size: 10
Sources:
Proteinuria 30%
300 mg multiple, topical
Studied dose
Dose: 300 mg
Route: topical
Route: multiple
Dose: 300 mg
Sources:
unhealthy, 40 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 40 years
Sex: M
Population Size: 10
Sources:
Papular urticarial eruption 70%
300 mg multiple, topical
Studied dose
Dose: 300 mg
Route: topical
Route: multiple
Dose: 300 mg
Sources:
unhealthy, 40 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 40 years
Sex: M
Population Size: 10
Sources:
Corneal opacity 80%
300 mg multiple, topical
Studied dose
Dose: 300 mg
Route: topical
Route: multiple
Dose: 300 mg
Sources:
unhealthy, 40 years
n = 10
Health Status: unhealthy
Condition: onchocerciasis
Age Group: 40 years
Sex: M
Population Size: 10
Sources:
Dyspnea grade 2, 2%
6 mg/kg 1 times / day single, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 6 mg/kg, 1 times / day
Co-administed with::
ivermectin(200 ug/kg; single)
albendazole(400 mg; single)
Sources:
unhealthy, median age 35 years
n = 43
Health Status: unhealthy
Condition: Filariasis
Age Group: median age 35 years
Sex: M+F
Population Size: 43
Sources:
Eye swelling grade 2, 2%
6 mg/kg 1 times / day single, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 6 mg/kg, 1 times / day
Co-administed with::
ivermectin(200 ug/kg; single)
albendazole(400 mg; single)
Sources:
unhealthy, median age 35 years
n = 43
Health Status: unhealthy
Condition: Filariasis
Age Group: median age 35 years
Sex: M+F
Population Size: 43
Sources:
Joint pain grade 2, 2%
6 mg/kg 1 times / day single, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 6 mg/kg, 1 times / day
Co-administed with::
ivermectin(200 ug/kg; single)
albendazole(400 mg; single)
Sources:
unhealthy, median age 35 years
n = 43
Health Status: unhealthy
Condition: Filariasis
Age Group: median age 35 years
Sex: M+F
Population Size: 43
Sources:
Nausea grade 2, 2%
6 mg/kg 1 times / day single, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 6 mg/kg, 1 times / day
Co-administed with::
ivermectin(200 ug/kg; single)
albendazole(400 mg; single)
Sources:
unhealthy, median age 35 years
n = 43
Health Status: unhealthy
Condition: Filariasis
Age Group: median age 35 years
Sex: M+F
Population Size: 43
Sources:
Rash grade 2, 2%
6 mg/kg 1 times / day single, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 6 mg/kg, 1 times / day
Co-administed with::
ivermectin(200 ug/kg; single)
albendazole(400 mg; single)
Sources:
unhealthy, median age 35 years
n = 43
Health Status: unhealthy
Condition: Filariasis
Age Group: median age 35 years
Sex: M+F
Population Size: 43
Sources:
Vomiting grade 2, 2%
6 mg/kg 1 times / day single, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 6 mg/kg, 1 times / day
Co-administed with::
ivermectin(200 ug/kg; single)
albendazole(400 mg; single)
Sources:
unhealthy, median age 35 years
n = 43
Health Status: unhealthy
Condition: Filariasis
Age Group: median age 35 years
Sex: M+F
Population Size: 43
Sources:
Fatigue grade 2, 5%
6 mg/kg 1 times / day single, oral
Studied dose
Dose: 6 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 6 mg/kg, 1 times / day
Co-administed with::
ivermectin(200 ug/kg; single)
albendazole(400 mg; single)
Sources:
unhealthy, median age 35 years
n = 43
Health Status: unhealthy
Condition: Filariasis
Age Group: median age 35 years
Sex: M+F
Population Size: 43
Sources:
Muscular pain 14%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Nodule 15%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Vomiting 16%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Convulsion 2%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Neck pain 24%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Nausea 28%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Chest pain 33%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Epididymal tenderness 34%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Abdominal pain 37%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Lymph node tenderness 38%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Joint pain 40%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Chills 45%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Malaise 49%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Vertigo 57%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Headache 65%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Fever 69%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Tinnitus 8%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Eruption <1%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Shock <1%
8 mg/kg 3 times / day multiple, oral (mean)
Studied dose
Dose: 8 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 3 times / day
Sources:
unhealthy
n = 972
Health Status: unhealthy
Condition: filariasis
Sex: M+F
Population Size: 972
Sources:
Overview

Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [Activation >10 uM]
no
no
no
no
no
yes [Inhibition 10 uM]
yes [Inhibition 10 uM]
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely
no
no (co-administration study)
Comment: Coadministration of refampicin/ketoconazole did not affect the exposure of diethylcarbamazine.
no
no (co-administration study)
Comment: Coadministration of refampicin/ketoconazole did not affect the exposure of diethylcarbamazine.
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
A brief introduction to the research achievement on the strategy and technical measures for interrupting the transmission of lymphatic filariasis in China.
2001
Compliance with the mass chemotherapy program for lymphatic filariasis.
2001 Dec
A community-based trial for the control of lymphatic filariasis and iodine deficiency using salt fortified with diethylcarbamazine and iodine.
2001 Dec
Lymphatic filariasis in kenya since 1910, and the prospects for its elimination: a review.
2001 Nov
Anthelmintics: a review.
2001 Oct-Dec
Mass DEC campaign for filariasis in a hyper endemic district of West Bengal.
2001 Sep
Lymphatic filariasis.
2001 Sep 20-26
[Technical measures of filariasis elimination in Tengzhou City].
2002
Carbamazepine-provoked hepatotoxicity and possible aetiopathological role of glutathione in the events. Retrospective review of old data and call for new investigation.
2002
Subconjunctival Loa Loa worm: case report.
2002
Genetic variability of the human filarial parasite, Wuchereria bancrofti in South India.
2002 Apr
The impact of single-dose diethylcarbamazine treatment of bancroftian filariasis in a low-endemicity setting in Egypt.
2002 Aug
Operational issues in the control of the vectors of Brugia.
2002 Dec
Progress towards, and challenges for, the elimination of filariasis from Pacific-island communities.
2002 Dec
Detection of Onchocerca volvulus infection in low prevalence areas: a comparison of three diagnostic methods.
2002 Dec
Antigenemia at 10 years after diethylcarbamazine treatment of asymptomatic microfilaraemic individuals: marginal conversion to infection-free state.
2002 Feb
Resurgence in filarial transmission after withdrawal of mass drug administration and the relationship between antigenaemia and microfilaraemia--a longitudinal study.
2002 Jan
Prevalence and intensity of Wuchereria bancrofti antigenaemia in Sri Lanka by Og4C3 ELISA using filter paper-absorbed whole blood.
2002 Jan-Feb
[Recommendations for the treatment of bancroftian filariasis in symptomless and diseased patients].
2002 Jan-Feb
New goals set for filariasis elimination in India.
2002 Jul
Efficacy of co-administration of albendazole and diethylcarbamazine against geohelminthiases: a study from South India.
2002 Jun
Mass drug administration to treat lymphatic filariasis.
2002 Jun 1
Chemotherapeutic approaches to nematodes: current knowledge and outlook.
2002 Mar
Filarial lymphoedema and alpha-1-adrenergic receptor blockade.
2002 Mar
Microfilaria in thyroid aspirate.
2002 Mar
Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects.
2002 Mar
Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of posttreatment reactions.
2002 Mar 15
Young male with pancytopenia: an unusual cause.
2002 May
Case 1-2002: Loa loa.
2002 May 30
Electron microscopic and molecular identification of Wolbachia endosymbionts from Onchocerca lupi: implications for therapy.
2002 May 30
Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells.
2002 Nov
Prevalence of diurnally subperiodic bancroftian filariasis among the Nicobarese in Andaman and Nicobar Islands, India: effect of age and gender.
2002 Nov
Case report: intraocular localization of Mansonella perstans in a patient from south Chad.
2002 Nov-Dec
Red blood cell antioxidant levels in Wuchereria bancrofti infection.
2002 Oct
Microfilaria in a thyroid nodule which resolved on treatment.
2002 Oct
Treatment of Brugia timori and Wuchereria bancrofti infections in Indonesia using DEC or a combination of DEC and albendazole: adverse reactions and short-term effects on microfilariae.
2002 Oct
The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole.
2002 Sep
The influence of the mass administration of diethylcarbamazine, alone or with albendazole, on the prevalence of filarial antigenaemia.
2002 Sep
The effect of six rounds of single dose mass treatment with diethylcarbamazine or ivermectin on Wuchereria bancrofti infection and its implications for lymphatic filariasis elimination.
2002 Sep
Efficacy and sustainability of a footcare programme in preventing acute attacks of adenolymphangitis in Brugian filariasis.
2002 Sep
Statistical issues in the assessment of the evidence for an interaction between factors in epilepsy trials.
2002 Sep 30
Targeting apoptotic signalling pathway and pro-inflammatory cytokine expression as therapeutic intervention in TPE induced lung damage.
2003
Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India.
2003 Apr
Long-term population migration: an important aspect to be considered during mass drug administration for elimination of lymphatic filariasis.
2003 Apr
Long-term follow-up of treatment with diethylcarbamazine on anti-filarial IgG4: dosage, compliance, and differential patterns in adults and children.
2003 Jan
Relationships between Wuchereria bancrofti microfilaria counts in human blood and parasite uptake and maturation in Culex pipiens, with observations on the effects of diethylcarbamazine treatment on these parameters.
2003 Mar
Setaria cervi: in vitro released collagenases and their inhibition by Wuchereria bancrofti infected sera.
2003 Mar
Strategic options for global lymphatic filariasis elimination.
2003 May
Ensuring supplies of quality diethylcarbamazine citrate (DEC).
2003 May
Lymphatic filariasis.
2003 May 16

Sample Use Guides

Lymphatic filariasis: 6 mg/kg daily for 12 days administered orally, preferably in divided doses after meals (W. bancrofti infection); 3-6 mg/kg daily for 6-12 days administered orally, preferably in divided doses after meals (B. malayi and B. timori infections). Tropical pulmonary eosinophilia: a dose of 8 mg/kg daily for 14 days repeated, as necessary, if symptoms return.
Route of Administration: Oral
Larvae of nocturnally subperiodic Brugia malayi was inhibited under incubation with diethylcarbamazine at concentration of 10(-5) M.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:56:45 UTC 2021
Edited
by admin
on Fri Jun 25 20:56:45 UTC 2021
Record UNII
OS1Z389K8S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIETHYLCARBAMAZINE CITRATE
EP   GREEN BOOK   HSDB   MART.   MI   ORANGE BOOK   USP   USP-RS   WHO-DD  
Common Name English
DIETHYLCARBAMAZINE CITRATE [GREEN BOOK]
Common Name English
LOXURAN
Common Name English
1-PIPERAZINECARBOXAMIDE, N,N-DIETHYL-4-METHYL-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE
Systematic Name English
DIETHYLCARBAMAZINI DIHYDROGENOCITRAS [WHO-IP LATIN]
Common Name English
NSC-80513
Code English
DIETHYLCARBAMAZINE CITRATE [USP-RS]
Common Name English
DIETHYLCARBAMAZINE CITRATE [USP]
Common Name English
DIETHYLCARBAMAZINE CITRATE [MART.]
Common Name English
DIETHYLCARBAMAZINE CITRATE [WHO-DD]
Common Name English
DIETHYLCARBAMAZINE CITRATE [JAN]
Common Name English
HETRAZAN
Brand Name English
DIETHYLCARBAMAZINE DIHYDROGEN CITRATE [WHO-IP]
Common Name English
DIETHYLCARBAMAZINE CITRATE [ORANGE BOOK]
Common Name English
DIETHYLCARBAMAZINE CITRATE [MI]
Common Name English
DIETHYLCARBAMAZINE CITRATE [HSDB]
Common Name English
ETHYLAMINOAZINE CITRATE
Common Name English
DIETHYLCARBAMAZINE CITRATE [USP MONOGRAPH]
Common Name English
N,N-DIETHYL-4-METHYL-1-PIPERAZINECARBOXAMIDE CITRATE (1:1)
Systematic Name English
Classification Tree Code System Code
CFR 21 CFR 520.622B
Created by admin on Fri Jun 25 20:56:45 UTC 2021 , Edited by admin on Fri Jun 25 20:56:45 UTC 2021
NCI_THESAURUS C250
Created by admin on Fri Jun 25 20:56:45 UTC 2021 , Edited by admin on Fri Jun 25 20:56:45 UTC 2021
CFR 21 CFR 520.622
Created by admin on Fri Jun 25 20:56:45 UTC 2021 , Edited by admin on Fri Jun 25 20:56:45 UTC 2021
CFR 21 CFR 520.622A
Created by admin on Fri Jun 25 20:56:45 UTC 2021 , Edited by admin on Fri Jun 25 20:56:45 UTC 2021
CFR 21 CFR 520.622C
Created by admin on Fri Jun 25 20:56:45 UTC 2021 , Edited by admin on Fri Jun 25 20:56:45 UTC 2021
Code System Code Type Description
EPA CompTox
1642-54-2
Created by admin on Fri Jun 25 20:56:45 UTC 2021 , Edited by admin on Fri Jun 25 20:56:45 UTC 2021
PRIMARY
DRUG BANK
DBSALT000975
Created by admin on Fri Jun 25 20:56:45 UTC 2021 , Edited by admin on Fri Jun 25 20:56:45 UTC 2021
PRIMARY
FDA UNII
OS1Z389K8S
Created by admin on Fri Jun 25 20:56:45 UTC 2021 , Edited by admin on Fri Jun 25 20:56:45 UTC 2021
PRIMARY
NCI_THESAURUS
C65379
Created by admin on Fri Jun 25 20:56:45 UTC 2021 , Edited by admin on Fri Jun 25 20:56:45 UTC 2021
PRIMARY
ECHA (EC/EINECS)
216-696-6
Created by admin on Fri Jun 25 20:56:45 UTC 2021 , Edited by admin on Fri Jun 25 20:56:45 UTC 2021
PRIMARY
MERCK INDEX
M4398
Created by admin on Fri Jun 25 20:56:45 UTC 2021 , Edited by admin on Fri Jun 25 20:56:45 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL684
Created by admin on Fri Jun 25 20:56:45 UTC 2021 , Edited by admin on Fri Jun 25 20:56:45 UTC 2021
PRIMARY
CAS
1642-54-2
Created by admin on Fri Jun 25 20:56:45 UTC 2021 , Edited by admin on Fri Jun 25 20:56:45 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DIETHYLCARBAMAZINE DIHYDROGEN CITRATE
Created by admin on Fri Jun 25 20:56:45 UTC 2021 , Edited by admin on Fri Jun 25 20:56:45 UTC 2021
PRIMARY Description: A white, crystalline powder; odourless or almost odourless.Solubility: Very soluble in water; soluble in 35 parts of ethanol (~750 g/l) TS; practically insoluble in ether R.Category: Filaricide.Storage: Diethylcarbamazine dihydrogen citrate should be kept in a tightly closed container, protected from light.Additional information: Diethylcarbamazine dihydrogen citrate is hygroscopic; it has an acid and bitter taste. Even in the absenceof light, Diethylcarbamazine dihydrogen citrate is gradually degraded on exposure to a humid atmosphere, the decompositionbeing faster at higher temperatures.Definition: Diethylcarbamazine dihydrogen citrate contains not less than 98.0% and not more than 101.0% of C10H21N3O,C6H8O7, calculated with reference to the anhydrous substance.
EVMPD
SUB01686MIG
Created by admin on Fri Jun 25 20:56:45 UTC 2021 , Edited by admin on Fri Jun 25 20:56:45 UTC 2021
PRIMARY
RXCUI
203175
Created by admin on Fri Jun 25 20:56:45 UTC 2021 , Edited by admin on Fri Jun 25 20:56:45 UTC 2021
PRIMARY RxNorm
USP_CATALOG
1193006
Created by admin on Fri Jun 25 20:56:45 UTC 2021 , Edited by admin on Fri Jun 25 20:56:45 UTC 2021
PRIMARY USP-RS
HSDB
6421
Created by admin on Fri Jun 25 20:56:45 UTC 2021 , Edited by admin on Fri Jun 25 20:56:45 UTC 2021
PRIMARY
PUBCHEM
15432
Created by admin on Fri Jun 25 20:56:45 UTC 2021 , Edited by admin on Fri Jun 25 20:56:45 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY